Search research articles
Contact Us
Filters
Showing results (41-50 of 134) with videos related to
Page
of 14
Sort By:
Breast Cancer Research and Treatment
|
August 9, 2020
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy
Carly Bess Williams, Caroline A Nebhan, Jinming Yang, et al.
Cancer
|
April 12, 2013
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort
Liana D Castel, Katherine E Hartmann, Ingrid A Mayer, et al.
Breast Cancer Research : BCR
|
September 7, 2018
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schöffski, Sara Cresta, Ingrid A Mayer, et al.
Breast Cancer Research and Treatment
|
December 25, 2014
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney, Howard Burris, Elaina Gartner, et al.
Clinical Breast Cancer
|
December 14, 2021
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)
Julie A Means-Powell, Ingrid A Mayer, Roohi Ismail-Khan, et al.
Magnetic Resonance Imaging
|
January 16, 2007
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results
Thomas E Yankeelov, Martin Lepage, Anuradha Chakravarthy, et al.
Ecancermedicalscience
|
August 13, 2014
Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?
Carrie G Lenneman, Wissam M Abdallah, Holly M Smith, et al.
NPJ Breast Cancer
|
June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer
Jessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2006
Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer
A Bapsi Chakravarthy, Mark C Kelley, Bernadette McLaren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2016
<sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Yingbing Wang, Karen L Ayres, Debra A Goldman, et al.
Page
of 14
Search research articles
Search
Showing results (41-50 of 134) with videos related to
Sort By:
Page
of 14
Breast Cancer Research and Treatment
|
August 9, 2020
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy
Carly Bess Williams, Caroline A Nebhan, Jinming Yang, et al.
Cancer
|
April 12, 2013
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort
Liana D Castel, Katherine E Hartmann, Ingrid A Mayer, et al.
Breast Cancer Research : BCR
|
September 7, 2018
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schöffski, Sara Cresta, Ingrid A Mayer, et al.
Breast Cancer Research and Treatment
|
December 25, 2014
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Sara Tolaney, Howard Burris, Elaina Gartner, et al.
Clinical Breast Cancer
|
December 14, 2021
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)
Julie A Means-Powell, Ingrid A Mayer, Roohi Ismail-Khan, et al.
Magnetic Resonance Imaging
|
January 16, 2007
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results
Thomas E Yankeelov, Martin Lepage, Anuradha Chakravarthy, et al.
Ecancermedicalscience
|
August 13, 2014
Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?
Carrie G Lenneman, Wissam M Abdallah, Holly M Smith, et al.
NPJ Breast Cancer
|
June 21, 2025
A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer
Jessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2006
Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer
A Bapsi Chakravarthy, Mark C Kelley, Bernadette McLaren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2016
<sup>18</sup>F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Yingbing Wang, Karen L Ayres, Debra A Goldman, et al.
Page
of 14